Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2023-08-08 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022
Report Publication Announcement Classification · 95% confidence The document is titled as a "SUPPLEMENTAL ANNOUNCEMENT FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022". It references the 2022 Annual Report and provides additional details about awards granted under share incentive schemes during the reporting period. The document explicitly states it is a supplemental announcement and clarifies that the additional information does not affect other information contained in the 2022 Annual Report. The document length is 3014 characters, which is relatively short and consistent with an announcement rather than a full report. It does not contain full financial statements or comprehensive financial data but rather supplementary information related to the annual report. Therefore, this document is an announcement related to the annual report, not the annual report itself. According to the classification rules, such a document should be classified as a Report Publication Announcement (RPA) or Regulatory Filings (RNS). Since it is a supplemental announcement providing further information related to the annual report, the best fit is Report Publication Announcement (RPA).
2023-08-08 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on changes in authorised/registered share capital, issued shares, convertible bonds, and other share-related activities for Pharmaron Beijing Co., Ltd. It includes detailed tables of share capital changes, issuance, repurchase, and cancellation of shares, as well as references to circulars, AGM approvals, and poll results announcements. The document is submitted to the Hong Kong Exchanges and Clearing Limited and is titled as a "Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities." This type of document is regulatory in nature, providing updates on share capital and shareholding movements rather than being a full financial report, earnings release, or management discussion. It is not an announcement of a report publication but a substantive regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-08-04 English
SUPPLEMENTAL ANNOUNCEMENT FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022
Regulatory Filings Classification · 95% confidence The document is titled as a "SUPPLEMENTAL ANNOUNCEMENT FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022". It references the 2022 Annual Report and provides additional details related to the Share Incentive Scheme disclosed in that Annual Report. The document is relatively short (3014 characters) and serves to supplement or clarify information already published in the Annual Report rather than presenting the full report itself. It does not contain full financial statements or comprehensive financial performance data but rather additional information related to disclosures in the Annual Report. This fits the pattern of a Regulatory Filing (RNS) as it is an announcement providing further information related to a report, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2023-08-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2023. It details movements in authorised/registered share capital, issued shares, convertibles, and other share-related information. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes detailed tables of share capital changes, share issuance, and convertible bonds. The document is a regulatory filing related to share capital movements and securities, consistent with a monthly return filing under exchange listing rules. It is not an annual or interim report, earnings release, or management discussion. It is not a proxy, AGM material, or voting results announcement. It is a regulatory compliance document reporting share capital and securities movements. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (over 10,000 characters) and detailed data confirm it is not a mere announcement but a substantive regulatory filing.
2023-08-03 English
INSIDE INFORMATION ANNOUNCEMENT REGARDING THE ESTIMATE FOR INTERIM RESULTS OF 2023
Earnings Release Classification · 95% confidence The document is an announcement titled 'INSIDE INFORMATION ANNOUNCEMENT REGARDING THE ESTIMATE FOR INTERIM RESULTS OF 2023' by Pharmaron Beijing Co., Ltd. It provides estimated financial results for the interim period January 1, 2023 to June 30, 2023, including revenue, net profit, and non-IFRS adjusted net profit. The announcement explicitly states that the results estimate has not been audited or pre-audited by certified public accountants and that the detailed interim report will be published later. The document is a preliminary earnings estimate rather than a full interim report containing audited financial statements or substantive financial data. It is longer than 5,000 characters but does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it serves as an earnings update or earnings guidance for the interim period. According to the filing definitions, an initial announcement of quarterly/periodical financial results (key highlights only) fits the Earnings Release (ER) category. Therefore, this document should be classified as an Earnings Release (ER). H1 2023
2023-07-28 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Pharmaron Beijing Co., Ltd. It references specific listing rules from the Stock Exchange of Hong Kong (SEHK) and details share issuance and capitalization shares. The content includes detailed tables of share counts before and after issuance, issue prices, and confirmations by the board of directors. This is a regulatory disclosure about share capital changes, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive data and confirmations. The document fits the category of Share Issue/Capital Change announcements, as it reports on changes in issued share capital and share buybacks as required by exchange rules.
2023-07-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.